Immune Oncology Program News Today

Hetty E. Carraway, MD, MBA, discusses the importance of testing for targetable mutations in patients with relapsed/refractory acute myeloid leukemia.

Leland Metheny, MD, discusses how agents such as Iomab-B have potential to shift practice in the hematologic malignancy space.

Changchun Deng, MD, PhD, discusses the mechanism of action and advantageous features of pirtobrutinib for patients with chronic lymphocytic leukemia.

Changchun Deng, MD, PhD, discusses factors to consider when sequencing covalent BTK inhibitors and venetoclax in patients with CLL/SLL.

Leland Metheny, MD, discusses ongoing clinical trials and their implications for the field of hematologic oncology.

Jan Joseph Melenhorst, PhD, emphasizes how research investigating chronic lymphocytic leukemia biology may result in more targeted CAR T-cell products.

A combined $1.35 million from the Dr. Ralph and Marian Falk Medical Research Trust was awarded to two researchers from the Case Western Reserve University School of Medicine to advance their work on finding more effective treatments-;and better options-;for two debilitating diseases.

ST. CLAIRSVILLE — Ohio Cancer Research is making ready for the 27th Grand Illusions Saute to raise funds for the fight against cancer, and this year’s guest

/PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases,...

Chimeric Therapeutics Ltd (ASX:CHM) has entered into a sponsored research agreement (SRA) with Case Western Reserve University (CWRU) to further advance its...